Please login to the form below

Not currently logged in

Pfizer UK appoints Erik Nordkamp as new managing director

He takes over from Jonathan Emms who moves to a global role within the firm

Erik Nordkamp has been appointed as the new managing director and head of the global innovative pharmaceutical business for Pfizer UK.

Nordkamp will take over from Jonathan Emms, who becomes global marketing lead for Pfizer's global established pharmaceutical (GEP) business.

This is a major step up for Emms as GEP has just been significantly boosted by Pfizer's recent $17bn acquisition of injectable medicine specialist Hospira.

Emms led Pfizer's UK business for three years, and in the past year has also served as ABPI president - a role he will be stepping down from in April in order to focus on his new position.

Emms has been at the forefront of the drug pricing debate in the UK as he was both Pfizer UK's general manager and the ABPI president during the negotiations and launch of the new PPRS scheme in January 2014.

Emms said: “I have thoroughly enjoyed leading the Pfizer UK business and it's been a great privilege to serve as ABPI president this past year.

“I'm proud of what has been achieved in both roles and I'd like to see dialogue continue with government in order to improve access and uptake of innovative medicines for UK patients, and achieve the government's aspiration of making the UK a leader in life sciences.”

New leader at Pfizer UK

Nordkamp joined Pfizer in 2010 and for the past year has led Pfizer Greece, Cyprus and Malta, as well as the global innovative pharmaceutical business.

Prior to this, he worked for Pfizer in the UK as head of strategy for primary care, Europe and Canada.

Nordkamp has also served as president of the PhRMA Innovation trade association and prior to joining Pfizer in 2010 he worked for Lilly in Germany and Australia.

Commenting on his appointment, Nordkamp said: “I am delighted to be returning to the UK, a key global hub for scientific innovation. However, with a National Health Service under strain, the UK is in a situation where patients are not always able to gain access to the most innovative medicines.

“Industry can play a vital role in finding solutions to these challenges, and I look forward to continuing conversations with government, the NHS and NICE to ensure the value of our industry is recognised, and health is seen as a longer term investment rather than a short-term cost. Patients have a right to get the right medicines at the right time.”

Article by
Ben Adams

10th February 2015

From: Research, Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....